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Abstract 
All chronic wounds are colonised by bacteria; for some, colonisation progresses to become infection. 
Alginate wound dressings are used for highly exuding chronic wounds as they are very absorbent, 
taking up large quantities of exudate while maintaining a moist wound bed to support healing. Some 
alginate dressings are doped with antimicrobials, most commonly silver, but evidence regarding the 
efficacy of these is largely inconclusive. This manuscript describes the development and in vitro 
assessment of alginate materials doped with chlorhexidine hexametaphosphate (CHX-HMP), a 
sparingly soluble salt which when exposed to aqueous environments provides sustained release of 
the common antiseptic chlorhexidine. Comparator materials were a commercial silver alginate 
dressing material and an alginate doped with chlorhexidine digluconate (CHXdg). CHX-HMP alginates 
provided a dose-dependent CHX release which was sustained for over 14 days, whereas CHXdg 
alginates released limited CHX and this ceased within 24 h. CHX-HMP and silver alginates were 
efficacious against 5 major wound pathogens (MRSA, E. coli, P. aeruginosa, K pneumoniae, A. 
baumannii) in a total viable count (TVC) and an agar diffusion zone of inhibition (ZOI) model. At 
baseline the silver alginate was more effective than the CHX-HMP alginate in the TVC assay but the 
CHX-HMP alginate was the more effective in the ZOI assay. After 7 days’ artificial aging the CHX-HMP 
alginate was more effective than the silver alginate for four of the five bacteria tested in both assays. 
These materials may ultimately find application in the development of wound dressings for chronic 
wounds that provide sustained antimicrobial protection.  
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Introduction 
Chronic wounds present substantial challenges to healthcare practitioners and are a source of 
discomfort and debility to millions of people worldwide. Among the most common chronic wounds 
are diabetic foot ulcers and venous leg ulcers, both of which are becoming more numerous as the 
population ages. Since 1980, the number of adults with type 2 diabetes has almost quadrupled, with 
lower and middle income countries the most affected [1]; 25% of these people will develop a 
diabetic foot ulcer in their lifetime, and 50% of those will become infected [2]. Venous ulcers are the 
most common chronic leg wounds, and prevalence rises with age, affecting 1.7% of people over 65 
[3]. All of these chronic wounds can be considered to be colonised by bacteria; only some progress 
to clinical infection, and the factors which determine whether and when this occurs are not well 
understood, resulting in uncertainty as to how to best prevent and treat them [4].  
Alginate-based dressings are used to dress many chronic wounds, including diabetic foot and venous 
leg ulcers. Alginate dressings are highly absorbent, absorbing 15-20x their weight in fluid; wound 
exudate is taken up by the dressing which forms into a gel, preventing leakage and maintaining a 
moist environment to support healing [5]. Antimicrobial alginate dressings are available, most 
commonly containing silver as the antimicrobial agent. While there is some evidence that silver-
impregnated dressings, including but not limited to alginates, can improve short-term healing of leg 
wounds, there is insufficient evidence to conclude whether these improve healing long-term [6]. 
There is also insufficient evidence to conclude whether they aid healing of diabetic foot ulcers [7], 
and a Cochrane review of the efficacy of silver to prevent wound infection found low quality 
evidence to suggest that silver products can detrimentally affect wound healing [8]. There is in vitro 
evidence to indicate that the antimicrobial efficacy of silver alginate dressings diminishes over time, 
with an agar diffusion assay revealing a reduction in zone of inhibition of 60% after 1 day and no 
zone at all at 7 days [9].  
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Chlorhexidine (CHX) is a broad-spectrum antiseptic used widely in health care. In wound care it is 
most commonly used as a pre-operative skin disinfectant, in the form of a solution of CHX 
digluconate, and in this use it is accepted to be effective in reducing the microbial population on the 
skin [10]. It is also used as a component of some dressings, although less commonly than silver, and 
not in conjunction with alginate, at least in a commercial product. The most commonly encountered 
dressing making use of CHX are securement devices for catheters for vascular access; these are 
usually composed of CHX-impregnated polyurethane foam or polyurethane-coated gel, and have 
been found to reduce catheter microbial colonisation and consequent catheter-related blood stream 
infection [11].  
Commercial CHX products including the vascular access devices described above employ CHX 
digluconate, which is readily soluble in water. This has limited its use in dressings, particularly those 
which are required to absorb a large quantity of exudate, as the solubility of the CHX salt means that 
it is released rapidly on contact with wound fluid, resulting in a high initial concentration and no 
sustained release. Recently, condensed phosphate salts of CHX have been reported [12]. CHX 
hexametaphosphate (CHX-HMP) is a sparingly soluble CHX salt which, when in contact with aqueous 
media, effects a slow release of soluble, active, CHX over an extended period, the duration of which 
and the resultant concentration of CHX in the local environment being dependent on factors such as 
fluid flow. The aim of this study was to explore whether alginate doped with CHX-HMP could have 
sustained and effective antimicrobial properties that may support its ultimate use in absorbent 
dressings for chronic wounds.  
Materials and methods 
Other than where stated, all chemicals and reagents were supplied by Sigma-Aldrich (Gillingham, 
UK). 
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Synthesis and analysis of CHX-HMP  
Equal volumes of CHX digluconate (CHXdg) (10 mM) and sodium hexametaphosphate (10 mM) were 
rapidly and simultaneously poured into a beaker being rapidly stirred. The resulting suspension of 
CHX-HMP particles was used on the same day and ultrasonicated (Grant MXB6 ultrasonicating water 
bath, Grant Instruments, Cambridge, UK) for 15 min immediately prior to use. To obtain pure CHX-
HMP for chemical analysis the suspension was cooled in ice and Büchner filtered, the filtrate washed 
with ice cooled water and obtained as a white amorphous solid. Ultraviolet (UV) spectrophotometry 
of CHX-HMP suspensions and CHXdg solutions was performed using a Lambda 35 
spectrophotometer (Perkin Elmer, Massachusetts, USA). FT-IR spectra of CHX-HMP precipitate were 
recorded in the range 650-4000 cm-1 using a Spectrum 100 (Perkin Elmer, Massachusetts, USA) and 
peaks reported as νmax (neat)/cm-1 which refers to νmax in wavenumbers. Elemental analysis for C, 
H, N and P was carried out by the University of Bristol microanalytical laboratory. Other properties of 
the CHX-HMP have been reported in earlier publications [12–14].  
Preparation and characterisation of alginate films containing CHX-HMP or CHXdg 
PROTANAL LF10/60FT (FMC Health and Nutrition, Philadelphia, USA), a ‘high G’ alginate with a G:M 
ratio of 60-70:30-40, was used. A 2 wt% aqueous solution of alginate was prepared by adding dry 
alginate to a rapidly stirring aqueous suspension of CHX-HMP equivalent to 6, 3, 1, 0.5, 0.1, 0.05 and 
0.01 wt% (for comparison: [CHX] = 4.88 mM for 6 wt%). Alginate films prepared without any CHX are 
denoted Alg-ctrl. Specimens are denoted as X-CHX-HMP where X refers to the wt% CHX-HMP in the 
alginate; for example, 6-CHX-HMP dressings contain 6 wt% CHX-HMP. 17.5 g of the suspensions 
were poured into petri dishes (ø = 90 mm) and the water allowed to evaporate at room temperature 
for 3 days. CaCl2 (30 mL, 0.18 M, 2 wt%) was added to the petri dishes for 25 min to permit cross-
linking. The cross-linked alginate films, which were ~1 mm thick, were then removed from the petri 
dishes, washed with distilled water and air dried on parafilm. CHXdg alginate films were prepared as 
for CHX-HMP films by dissolving the alginate in CHXdg solution diluted to the required 
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concentration, instead of the CHX-HMP suspension, and these are referred to as X-CHXdg where X 
again represents the concentration of CHX-HMP that provides the equivalent concentration of CHX 
in the material. Disk shaped specimens (ø = 10 mm) were cut from theses material and used for 
subsequent work. 6-CHX-HMP and Alg-ctrl films were analysed using atomic force microscopy (AFM; 
Nanoscope IIIa, Veeco, New York, USA) in tapping mode with topography and phase imaging.  
Tegaderm Alginate AgTM (3M, Minnesota, USA; abbreviated to ‘Ag-Alg’), a commercially available 
non-woven fibrous alginate mat containing silver sodium hydrogen zirconium phosphate as an active 
antibacterial agent, was used as a positive control. Disks (ø = 10 mm) were cut from this material 
under sterile conditions and these used for subsequent work.  
In some instances, specimens of 6-CHX-HMP and Ag-Alg were investigated after a period of aging to 
assess the properties of the material after a period of use. To age specimens, disks were sealed in 
air-tight sterile KilnerTM jars containing distilled water (2.25 mL per disk). Jars remained stationary for 
seven days with 4x inversion on day 1, 3 and 7. Specimens were then removed, rinsed, immersed in 
water (1 min), rinsed, air dried and used. 
Chlorhexidine elution from dressings 
CHX elution was assessed using UV spectroscopy at 254 nm with CHX concentration derived by 
comparison to CHXdg standards at 5-50 µM CHX. Alginate disks with 3- and 6-CHX-HMP and 6-CHXdg 
were placed in individual semi-micro cuvettes (BRAND® semi-micro cuvettes, BRAND GMBH + CO 
KG, Wertheim, Germany), covered with distilled water (2.25 mL) and the cuvette sealed with a lid 
and parafilm (n = 30 for each CHX doping). Cuvettes were agitated throughout using a New 
Brunswick Scientific G-25 incubator shaker at 150 rpm and 37°C (Eppendorf, Hamburg, Germany) 
and the absorbance (254 nm) was recorded frequently over a two-week period. 
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Microbial growth inhibition assays 
Microbiological assays were conducted using: Methicillin-resistant Staphylococcus aureus EMRSA-15, 
Pseudomonas aeruginosa ATCC9027, Escherichia coli NCTC10418, Klebsiella pneumoniae ATCC10031 
and Acinetobacter baumannii 121J6. Bacteria suspensions were equilibrated to a 0.5 MacFarland 
standard which is approximately 1.5 x 108 colony forming units (CFU)/mL at A600. All bacteria were 
cultured aerobically at 37°C in nutrient broth.  
To establish total viable counts (TVC) of bacteria incubated with the alginate materials, single 10 mm 
disk specimens of Alg-ctrl, 3-CHX-HMP, 6-CHX-HMP and Ag-Alg were placed in sterile, 5 mL plastic 
bijou containers containing 1 mL nutrient broth and inoculated with equilibrated bacterial 
suspension (10 μL). Each bacterium was tested separately, and nine repeats of each material-
bacteria combination were assessed. The culture from each vial was discarded following incubation 
(24 h, 37°C), and each specimen transferred into a fresh container containing 1 mL phosphate-
buffered saline (PBS). This was vortexed (2200 rpm, 20 s) dislodging any bacteria contained within 
the specimens into the PBS. Serial dilutions (10-1 - 10-12) were prepared using PBS, these were 
enumerated using the TVC method [15].  
To assess zones of inhibition (ZOI) in an agar diffusion model, bacterial lawns (100 μL) were prepared 
on a nutrient agar plate (ø = 90 mm) using the spread plate method and allowed to air-dry before 
specimens were placed onto the lawns.  These were incubated (24 h, 37°C) and any ZOI measured 
using digital callipers. Each bacterium was tested separately; nine repeats of each material-bacteria 
combination were assessed. 
Results  
Characterisation of CHX-HMP particles and alginate films 
A bathochromic shift in the UV absorption maximum of CHX accompanies the reaction between CHX 
and HMP, from 254 to 268 nm (Figure 1) [16], suggesting an increase in delocalisation within the 
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molecular structure. This indicates that an electrostatic interaction between the polar groups of 
each individually soluble ion - biguanides and phosphates - is involved in the reaction.  
Using Büchner filtration, CHX-HMP was obtained as a white amorphous solid. Elemental analysis is 
shown in Table 1, and compared with predicted values using a 3:1 CHX:HMP ratio, i.e. 
[C22H28Cl2N10]3[O18P6]. FTIR spectra are shown in Figure 2 and indicated νmax (neat): 3321 (NH), 3150 
(C-Hchlorophenyl), 2936 & 2860 (C-Hmethanediyls), 1628 (ArNHC(=N-H)NHAr) (aromatic guanidine 
absorptions), 1604 ((CH3)2NC(=N-H)C(CH3)2) (aliphatic guanidine absorptions), 1580 & 1524 (C=N & 
C=Caromatic), 1490 (C-Hmethanediyl), 1420 (C=N & C=Caromatic), 1239 (P=O), 1071 (P-O), 1012 (C=N & 
C=Caromatic), 867 (P-O-P), 824 (C-Haromatic), 729 (C-Claromatic) cm-1 [17–23].  
AFM topography images indicated a rough surface texture for both Alg-ctrl and those containing 
CHX-HMP, but phase imaging revealed evidence of variation in stiffness and subsurface 
heterogeneity in the CHX-HMP-impregnated alginate which were not observed in the control 
alginate Alg-ctrl (Figure 3).  
Chlorhexidine elution from dressings  
Elution of CHX from 6-CHX-HMP and 6-CHXdg alginate films are shown in Figure 4. Elution of CHX 
from the CHXdg film ceased at ~22 hours whereas for the CHX-HMP film CHX release was more 
sustained and was still ongoing at 16 days. A linear dose response was observed; the average elution 
of CHX from alginate with 3-CHX-HMP loading over the period was 50% of that of 6-CHX-HMP 
loading (data not shown).  
Microbial growth inhibition assays 
TVCs after 24 h immersion with specimens as prepared and after 7 days’ aging are shown in Table 2, 
and ZOI in Table 3. The CHX-HMP and commercial silver alginate materials all showed significant 
antimicrobial efficacy in the TVC and agar diffusion models. The CHX-HMP showed a dose response, 
with alginates containing more CHX-HMP effecting a greater reduction in TVCs and a larger ZOI. The 
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ZOI of a wide range of CHX-HMP loadings was investigated to establish the minimum CHX-HMP that 
still showed a ZOI; this varied from 0.05 wt% to 1 wt% depending on the species of microbe. The 3-
CHX-HMP and 6-CHX-HMP alginates showed greater ZOI with all microbes except A. baumannii, but 
less reduction in TVC, than the silver alginate. When the silver and 6-CHX-HMP alginates were 
subjected to 7 days’ aging in distilled water, the CHX-HMP alginates showed greater ZOI than the 
silver alginate and a greater reduction in TVCs, since aged silver alginates showed no reduction in 
TVCs whereas CHX-HMP alginates reduced TVCs by at least a factor of 10 except for P. aeruginosa. 
Discussion 
Alginate is a biocompatible polysaccharide used widely in wound dressing products due to its ability 
to absorb exudate and establish a moist environment supportive of healing whilst retaining its 
mechanical integrity [24]. Antimicrobials and other drugs embedded within the alginate can help to 
manage bioburden within the dressing and may also be used to deliver drug directly to the wound 
bed. The aim of incorporating CHX-HMP into an alginate matrix was to establish whether alginate 
was a suitable matrix for the use of CHX-HMP in antimicrobial wound dressings. CHX is widely used 
in wound care but more commonly as a skin disinfectant and in intravenous securement devices 
rather than in dressings for chronic wounds. However, clinicians are familiar with the broad-
spectrum efficacy of CHX and its long history of use and as such a sustained release CHX wound 
dressing might find favour among medical professionals supporting patients with chronic wounds. 
The polyphosphate counterion is benign, used as a food additive and in oral care products such as 
toothpastes. The mechanism of CHX release from CHX-HMP is understood to be a gradual 
dissolution of the CHX-HMP material followed by diffusion of the aqueous CHX ion.  
CHX-HMP was precipitated instantaneously upon mixing of aqueous solutions of CHX and HMP ions 
(Equation 1). The composition of the salt was found to be 3 CHX ions to 1 HMP ion (Table 1) with FT-
IR showing the absence of gluconate in the isolated CHX-HMP (Figure 2).  
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Equation 1. Precipitation of chlorhexidine hexametaphosphate from solutions of chlorhexidine 
digluconate and sodium hexametaphosphate. 
 
Alginate films were prepared with a range of dopings of CHX-HMP particles, and AFM phase mode 
images of 6-CHX-HMP films reveal the presence of stiff particulate inclusions whereas topography 
images were broadly indistinguishable from control alginate films (Figure 3), which is consistent with 
solid particles of CHX-HMP being embedded within the alginate film rather than on the surface. This 
is consistent with previous findings, in that CHX-HMP exhibits low solubility and a protracted 
equilibration in water [12], and as such it is highly unlikely that the CHX-HMP particles would 
dissolve during the process of preparing the alginate film. The opaque appearance of the CHX-HMP 
films compared with comparatively translucent control films provides further evidence that there 
were intact CHX-HMP particles present within the alginate. 
Films containing CHXdg were prepared using a solution of CHXdg containing the same wt% of CHX as 
the 6-CHX-HMP suspension, to compare the kinetics of the soluble CHX cation release from films 
prepared with CHX-HMP and CHXdg. CHX was released rapidly from films containing the highly 
soluble CHXdg, reaching completion in under 24 hours, whereas for the CHX-HMP films the CHX 
release continued for over 14 days, and was still ongoing at the conclusion of the measurements 
(Figure 4), illustrating that the alginate matrix supported the free diffusion of solubilised CHX out of 
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the alginate and into the surrounding environment, potentially aided by the presence of HMP which 
prevented the CHX from interacting with the alginate directly. Although the CHXdg films were 
prepared with the same total concentration of CHX as the CHX-HMP (allowing for both soluble and 
bound CHX), the total release of CHX from the CHXdg films was lower than that for CHX-HMP films. 
This might indicate that a proportion of the CHX from CHXdg was either not retained in the alginate 
or was removed during the cross-linking or brief rinsing periods required for preparation. 
Alternatively it might be that the CHX cation from CHXdg interacted and bound with the alginate 
itself, thus was not able to leach out of the film in the same way as the HMP-shielded CHX.  
The CHX-HMP alginate films showed a dose-dependent antimicrobial efficacy against laboratory 
strains of five common wound infecting pathogens. S. aureus, P. aeruginosa and E. coli were selected 
on the basis that they are some of the most common pathogens isolated from chronic wounds [25–
27]; a methicillin-resistant strain of S. aureus was utilised in this study on the basis of its importance 
in the hospital and community settings where chronic wounds are most commonly managed, and 
with respect to the observation that some MRSA strains exhibit reduced susceptibility to CHX [28], 
thus providing a more robust challenge to the novel CHX technology in this study. K. pneumoniae 
and A. baumannii have historically been less associated with chronic wounds, but these frequently 
multi-drug-resistant species are increasingly believed to play an important role in wound infections, 
particularly in wounds sustained by military personnel in conflict zones [29,30] and in burn wound 
infections [31,32].  
The microbial counting assessment conducted on bacteria incubated with alginate films indicated 
that CHX-HMP and Ag-Alg both reduced TVCs. When alginate films were used as prepared/supplied, 
the Ag-Alg effected a greater reduction in TVCs; no bacteria could be retrieved indicating a complete 
eradication of each species (109 reduction compared to the control alginate), whereas with 6-CHX-
HMP the reduction ranged from 101 (A. baumannii) to 105 (MRSA, E. coli) and with 3-CHX-HMP the 
reduction ranged from 101 (A. baumannii, K. pneumoniae, P. aeruginosa) to 104 (MRSA, E. coli). 
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However, after a 7 day period of aging the 6-CHX-HMP alginate retained some efficacy, reducing 
TVCs for four of the five bacteria with a reduction of 101 (E. coli, P. aeruginosa and A. baumannii) to 
103 (MRSA), failing only to reduce counts of K. pneumoniae. Given that K. pneumoniae produces a 
mucoid layer that renders the species particularly difficult to eradicate using antimicrobials, it is not 
surprising that this presented a greater challenge to the technology. The silver alginate, however, 
only reduced TVCs of A. baumannii (103) and did not reduce counts of the other species.  
The agar diffusion test findings illustrated a dose- and species-dependent efficacy of the CHX-HMP 
doped alginates. For some bacteria– MRSA, E. coli – a doping of as low as 0.05 wt% was sufficient to 
prevent microbial growth, whereas the threshold concentration was greater with the other 
bacteriatested; 0.5 wt% for P. aeruginosa and K. pneumoniae and 1 wt% for A. baumannii. For all 
bacteria, the greater the CHX-HMP concentration (above the threshold noted above), the larger the 
ZOI. The CHX-HMP alginates provided broadly comparable ZOI to the commercial silver alginate, 
although ZOI with CHX-HMP were slightly larger than with silver for MRSA, E. coli, P. aeruginosa and 
K. pneumoniae but slightly smaller with A. baumannii. After the alginates were aged for 7 days, the 
agar diffusion test showed broadly similar results, with both 6-CHX-HMP and commercial silver 
alginates showing a slight reduction in ZOI but a ZOI was nevertheless still observed with all bacteria 
tested. 
The 7 day aging protocol was adopted in order to allow any readily soluble, motile antimicrobial to 
be released, in analogy to the process of wound exudate building up in a dressing, which would 
usually remain in place on the wound for 7 days. The CHX-HMP technology is by design a controlled 
release material and as such it is important to consider whether its properties could support a 
product which retains its efficacy after a period of use of the device, in this case a dressing for a 
chronic wound. At first glance the two assays – TVC and agar diffusion – could be seen to be 
mutually contradictory, in that using the TVC assay aged silver alginates have lost the majority of 
their efficacy after aging while CHX-HMP alginates are still efficacious, although less so than at 
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baseline, whereas using the agar diffusion test there was little difference in performance between 
the materials. This apparent contradiction can be resolved by considering the two antimicrobial 
assays used. The agar diffusion model will inherently favour a silver device over a CHX technology, in 
that the ZOI is in part a reflection of how far across the agar the antimicrobial agent is able to 
diffuse, and a small ion such as silver will diffuse more readily than the much larger CHX [33]. For this 
reason, ZOI for silver-based dressings are routinely expected to be greater than for other 
antimicrobials, and this need not be taken to imply that this will translate into superior clinical 
performance [33]. Thus the barrier to efficacy in agar diffusion was less, and the reduction in silver 
owing to the aging did not eliminate all silver, such that a ZOI was still achieved with the residual 
silver present. The TVCs on the other hand are more equitable in terms of the assessment of the 
specific antimicrobial, and in this assay the reduction in silver’s efficacy after aging is clear (Table 2).  
The 7 day aging step is of course a radical simplification of the clinical environment of such a 
dressing. Nevertheless, such an assessment is necessary to ascertain whether an influx of wound 
exudate is likely to reduce the efficacy of the antimicrobial contained within. Alginate dressings are 
used especially for wounds with high levels of exudate. A fast releasing antimicrobial dressing will 
provide a large dose of antimicrobial initially, which may have undesired effects; for instance, the 
most common adverse event associated with the CHX-impregnated vascular access devices 
described above is contact dermatitis, owing to the high concentration of CHX released from these 
dressings [11]. Furthermore, if release is not sustained, the antimicrobial will be depleted by 
diffusion into the wound bed and binding to components of the bacterial cell wall. Our observations 
suggest that the CHX-HMP alginates had a greater longevity of antimicrobial efficacy than the 
commercial silver alginate.  
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Conclusions 
Alginate films with impregnated chlorhexidine hexametaphosphate nanoparticles (CHX-HMP) acted 
as reservoirs of chlorhexidine (CHX), eluting it into aqueous media in a dose- and time-dependent 
manner. The elution profile showed an immediate burst release followed by a sustained release over 
the two weeks monitored. By comparison, an equivalent material containing CHXdg released much 
less CHX and this was depleted after < 24 h. Dressings which display antimicrobial properties for 
substantially less than the time the dressing is usually left on the wound – commonly 7 days – may 
provide only shortlived protection and thereafter not offer effective prevention against infection.  
CHX-HMP impregnated alginates reduced total viable counts of a range of common wound infecting 
microorganisms: methicillin-resistant S. aureus (MRSA), P. aeruginosa, E. coli, K. pneumoniae and A. 
baumannii over 24 h in vitro. The reduction in TVC was less than that of a commercial silver alginate 
dressing at baseline, but greater than the silver alginate after a period of in vitro aging. The CHX-
HMP alginates exhibited a dose-dependent behaviour in an agar diffusion model, with contact 
inhibition at lower CHX-HMP concentrations (0.05 – 1 %) and remote inhibition at higher 
concentration (0.5 – 6%). The ZOI was reduced after aging but was still superior in 4 of the 5 
microbes to that of the silver alginate dressing.  
While the CHX-HMP alginate is an early prototype, and much optimisation of dose and distribution 
still remains to be carried out, these data indicate that the material may offer favourable properties 
for the development of sustained efficacy wound dressings for highly exuding, high infection risk 
wounds.  
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Figures 
 
 
 
 
 
 
 
Figure 1. UV absorption spectra of CHXdg solution and CHX-HMP suspension. There is a 
bathochromic shift in the first absorption maximum following the precipitation reaction, from 254 
nm for CHXdg to 268 nm for CHX-HMP. 
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Figure 2. FT-IR spectra of CHX-HMP, sodium hexametaphosphate (Na HMP) and chlorhexidine 
dihydrochloride (CHX-dHCl) 
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a b 
 
c d 
Figure 3. AFM images of alginate films. a: phase image and b: topography image of control film Alg-
ctrl; c: phase image and d: topography image of 6-CHX-HMP films. The x and y axes are 300 nm in 
each case. The z axis represents 40 degrees in the case of phase (a and c) and 10 nm in the case of 
topography (b and d). Both Alg-ctrl and 6-CHX-HMP films are rough in topography, but the Alg-ctrl 
film shows little phase variation compared with the 6-CHX-HMP film, indicating a variability in 
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stiffness of the 6-CHX-HMP film due to the presence of embedded hard, rigid CHX-HMP particles 
within the soft, flexible alginate film.  
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Figure 4. Cumulative CHX release from 6-CHX-HMP and CHXdg alginate films. Error bars represent 
standard deviations.  
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Tables 
Element Recorded Predicted using a 
3:1 CHX:HMP ratio 
C 40.1 39.8 
H 5.3 4.3 
N 20.0 21.1 
P 8.6 9.3 
Table 1. Elemental analysis of CHX-HMP precipitate 
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 Alg-ctrl 3-CHX-HMP 6-CHX-HMP alginate Ag-Alg 
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MRSA 3.6x109 3.3x108 1.8x105 104 6.8x104 105 1.6x105 103 0 109 3.6x108 NR 
E. coli 5.0x109 4.7x108 5.3x105 104 5.4x104 105 1.3x107 101 0 109 3.6x108 NR 
P. aeruginosa 6.8x107 1.9x108 7x106 101 8.0x104 103 5.8x107 101 0 107 3.8x108 NR 
K. pneumoniae 2.1x108 1.9x108 1.8x107 101 1.7x105 103 1.1x108 NR 0 108 1.9x108 NR 
A. baumannii  3.2x108 1.5x108 4.5x107 101 1.0x107 101 6.3x107 101 0 108 7.2x105 103 
Table 2. Total viable counts of 5 microbes after incubation with CHX-HMP alginates and a commercial silver alginate, with and without aging, and the 
reduction to the nearest factor of 10 with respect to the control alginate which contained no antimicrobial. NR = no reduction. 3-CHX-HMP specimens were 
not investigated after aging. The silver alginates show total kill at baseline but no antimicrobial efficacy after aging, with the exception of A. baumannii. The 
experimental CHX-HMP alginates show a dose response, with the 6-CHX-HMP effecting a greater reduction in CFU than 3-CHX-HMP, and show a sustained 
efficacy, with a reduction in CFU after aging, although this was less than the reduction in CFU without aging.   
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MRSA NZ NZ 12.1 13.9 16.6 19.6 21.0 22.6 15.5 18.0 11.7 
E. coli NZ NZ 10.3 11.2 13.1 14.7 18.4 19.7 12.9 16.9 12.5 
P. aeruginosa NZ NZ NZ NZ 10.5 10.6 13.5 14.2 12.1 14.1 12.5 
K. pneumoniae NZ NZ NZ NZ 10.8 12.7 15.6 16.5 11.9 14.1 11.9 
A. baumannii  NZ NZ NZ NZ NZ 10.7 13.0 14.9 16.1 12.3 13.3 
Table 3. Zones of inhibition in mm around 10 mm disk-shaped specimens of experimental alginates with a range of CHX-HMP loadings and a commercial 
silver alginate. The 6-CHX-HMP alginate and Ag-Alg were also investigated after 7 days’ aging. NZ indicates there was no zone; there were in some cases 
some limited inhibition of growth under the disk.  
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